-
1
-
-
84892805731
-
Cancer statistics, 2014
-
Siegel R, Ma J, Zou Z, et al. Cancer statistics, 2014. CA Cancer J Clin 2014;64(1):9-29
-
(2014)
CA Cancer J Clin
, vol.64
, Issue.1
, pp. 9-29
-
-
Siegel, R.1
Ma, J.2
Zou, Z.3
-
2
-
-
0015370976
-
Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate
-
Huggins C, Hodges CV. Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. CA Cancer J Clin 1972;22(4):232-40
-
(1972)
CA Cancer J Clin
, vol.22
, Issue.4
, pp. 232-240
-
-
Huggins, C.1
Hodges, C.V.2
-
3
-
-
51449087794
-
Targeting the androgen receptor pathway in prostate cancer
-
Chen Y, Sawyers CL, Scher HI. Targeting the androgen receptor pathway in prostate cancer. Curr Opin Pharmacol 2008;8(4):440-8
-
(2008)
Curr Opin Pharmacol
, vol.8
, Issue.4
, pp. 440-448
-
-
Chen, Y.1
Sawyers, C.L.2
Scher, H.I.3
-
4
-
-
84866770294
-
Increased survival with enzalutamide in prostate cancer after chemotherapy
-
Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012;367(13):1187-97
-
(2012)
N Engl J Med
, vol.367
, Issue.13
, pp. 1187-1197
-
-
Scher, H.I.1
Fizazi, K.2
Saad, F.3
-
5
-
-
84908450155
-
Enzalutamide in metastatic prostate cancer before chemotherapy
-
Beer TM, Armstrong AJ, Rathkopf DE, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 2014;371(5):424-33
-
(2014)
N Engl J Med
, vol.371
, Issue.5
, pp. 424-433
-
-
Beer, T.M.1
Armstrong, A.J.2
Rathkopf, D.E.3
-
6
-
-
4744366279
-
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer
-
Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351(15):1502-12
-
(2004)
N Engl J Med
, vol.351
, Issue.15
, pp. 1502-1512
-
-
Tannock, I.F.1
De Wit, R.2
Berry, W.R.3
-
7
-
-
4744337716
-
Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer
-
Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004;351(15):1513-20
-
(2004)
N Engl J Med
, vol.351
, Issue.15
, pp. 1513-1520
-
-
Petrylak, D.P.1
Tangen, C.M.2
Hussain, M.H.3
-
8
-
-
77957682309
-
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: A randomised open-label trial
-
de Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010;376(9747):1147-54
-
(2010)
Lancet
, vol.376
, Issue.9747
, pp. 1147-1154
-
-
De Bono, J.S.1
Oudard, S.2
Ozguroglu, M.3
-
9
-
-
84880428467
-
Alpha emitter radium-223 and survival in metastatic prostate cancer
-
Parker C, Nilsson S, Heinrich D, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 2013;369(3):213-23
-
(2013)
N Engl J Med
, vol.369
, Issue.3
, pp. 213-223
-
-
Parker, C.1
Nilsson, S.2
Heinrich, D.3
-
10
-
-
77955066199
-
Sipuleucel-t immunotherapy for castration-resistant prostate cancer
-
Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-t immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010;363(5):411-22
-
(2010)
N Engl J Med
, vol.363
, Issue.5
, pp. 411-422
-
-
Kantoff, P.W.1
Higano, C.S.2
Shore, N.D.3
-
11
-
-
79957443342
-
Abiraterone and increased survival in metastatic prostate cancer
-
de Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011;364(21):1995-2005
-
(2011)
N Engl J Med
, vol.364
, Issue.21
, pp. 1995-2005
-
-
De Bono, J.S.1
Logothetis, C.J.2
Molina, A.3
-
12
-
-
84872078210
-
Abiraterone in metastatic prostate cancer without previous chemotherapy
-
Ryan CJ, Smith MR, de Bono JS, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 2013;368(2):138-48
-
(2013)
N Engl J Med
, vol.368
, Issue.2
, pp. 138-148
-
-
Ryan, C.J.1
Smith, M.R.2
De Bono, J.S.3
-
13
-
-
65649090203
-
Development of a second-generation antiandrogen for treatment of advanced prostate cancer
-
Tran C, Ouk S, Clegg NJ, et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 2009;324(5928):787-90
-
(2009)
Science
, vol.324
, Issue.5928
, pp. 787-790
-
-
Tran, C.1
Ouk, S.2
Clegg, N.J.3
-
14
-
-
0031048446
-
The antiandrogen withdrawal syndrome in relapsed prostate cancer
-
discussion 24-27
-
Scher HI, Kolvenbag GJ. The antiandrogen withdrawal syndrome in relapsed prostate cancer. Eur Urol 1997;31(Suppl 2):3-7.discussion 24-27
-
(1997)
Eur Urol
, vol.31
, pp. 3-7
-
-
Scher, H.I.1
Kolvenbag, G.J.2
-
15
-
-
77952105685
-
Antitumour activity of mdv3100 in castration-resistant prostate cancer: A phase 1-2 study
-
Scher HI, Beer TM, Higano CS, et al. Antitumour activity of mdv3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet 2010;375(9724):1437-46
-
(2010)
Lancet
, vol.375
, Issue.9724
, pp. 1437-1446
-
-
Scher, H.I.1
Beer, T.M.2
Higano, C.S.3
-
16
-
-
77950574393
-
Structure-activity relationship for thiohydantoin androgen receptor antagonists for castration-resistant prostate cancer (crpc)
-
Jung ME, Ouk S, Yoo D, et al. Structure-activity relationship for thiohydantoin androgen receptor antagonists for castration-resistant prostate cancer (crpc). J Med Chem 2010;53(7):2779-96
-
(2010)
J Med Chem
, vol.53
, Issue.7
, pp. 2779-2796
-
-
Jung, M.E.1
Ouk, S.2
Yoo, D.3
-
18
-
-
84893349290
-
Improved outcomes in elderly patients with metastatic castrationresistant prostate cancer treated with the androgen receptor inhibitor enzalutamide: Results from the phase iii affirm trial
-
Sternberg CN, de Bono JS, Chi KN, et al. Improved outcomes in elderly patients with metastatic castrationresistant prostate cancer treated with the androgen receptor inhibitor enzalutamide: results from the phase iii affirm trial. Ann Oncol 2014;25(2):429-34
-
(2014)
Ann Oncol
, vol.25
, Issue.2
, pp. 429-434
-
-
Sternberg, C.N.1
De Bono, J.S.2
Chi, K.N.3
-
19
-
-
84907057471
-
Ar-v7 and resistance to enzalutamide and abiraterone in prostate cancer
-
Antonarakis ES, Lu C, Wang H, et al. Ar-v7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med 2014;371(11):1028-38
-
(2014)
N Engl J Med
, vol.371
, Issue.11
, pp. 1028-1038
-
-
Antonarakis, E.S.1
Lu, C.2
Wang, H.3
-
20
-
-
84882274167
-
Nf-kappab2/p52 induces resistance to enzalutamide in prostate cancer: Role of androgen receptor and its variants
-
Nadiminty N, Tummala R, Liu C, et al. Nf-kappab2/p52 induces resistance to enzalutamide in prostate cancer: role of androgen receptor and its variants. Mol Cancer Ther 2013;12(8):1629-37
-
(2013)
Mol Cancer Ther
, vol.12
, Issue.8
, pp. 1629-1637
-
-
Nadiminty, N.1
Tummala, R.2
Liu, C.3
-
21
-
-
48549089747
-
Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance
-
Dehm SM, Schmidt LJ, Heemers HV, et al. Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. Cancer Res 2008;68(13):5469-77
-
(2008)
Cancer Res
, vol.68
, Issue.13
, pp. 5469-5477
-
-
Dehm, S.M.1
Schmidt, L.J.2
Heemers, H.V.3
-
22
-
-
58249110391
-
Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer
-
Hu R, Dunn TA, Wei S, et al. Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res 2009;69(1):16-22
-
(2009)
Cancer Res
, vol.69
, Issue.1
, pp. 16-22
-
-
Hu, R.1
Dunn, T.A.2
Wei, S.3
-
23
-
-
62949147825
-
-
US Food and Drug Administration. European medicines agency. Available from: http://www.ema.europa.eu
-
European Medicines Agency
-
-
-
24
-
-
84924364276
-
Primary, secondary, and quality-of-life endpoint results from prevail, a phase 3 study of enzalutamide in men with metastatic castration resistant prostate cancer (mcrpc)
-
abstract 5007
-
Armstrong AJ, Tombal B, Sternberg CN, et al. Primary, secondary, and quality-of-life endpoint results from prevail, a phase 3 study of enzalutamide in men with metastatic castration resistant prostate cancer (mcrpc). J Clin Oncol 2014;32(5s):abstract 5007
-
(2014)
J Clin Oncol
, vol.32
, Issue.5 S
-
-
Armstrong, A.J.1
Tombal, B.2
Sternberg, C.N.3
-
25
-
-
84908575897
-
Effect of enzalutamide on time to first skeletalrelated event, pain, and quality of life in men with castration-resistant prostate cancer: Results from the randomised, phase 3 affirm trial
-
Fizazi K, Scher HI, Miller K, et al. Effect of enzalutamide on time to first skeletalrelated event, pain, and quality of life in men with castration-resistant prostate cancer: results from the randomised, phase 3 affirm trial. Lancet Oncol 2014;15(10):1147-56
-
(2014)
Lancet Oncol
, vol.15
, Issue.10
, pp. 1147-1156
-
-
Fizazi, K.1
Scher, H.I.2
Miller, K.3
|